Introduction: A tumor-to-tumor metastasis (TTM) is a rare metastatic process where a primary malignant tumor metastasizes to another tumor, most commonly a benign tumor such as a meningioma. Here, we present two recent cases of tumor-to-meningioma metastases (TMM) from our clinical practice and review of recent literature. The primary cancers were prostate and breast cancer, respectively.
Material And Methods: We reviewed the electronic medical records of the two patients and conducted a literature review of TTM, focusing on biological mechanisms related to TMM.
Results: Our first patient, a man with a history of stable prostate cancer, underwent resection of two WHO grade 1 meningiomas, and the largest tumor was found to have TMM. Our second patient, a woman with progressive breast cancer, was operated for a WHO grade II meningioma, and the meningioma harbored breast cancer metastases. TMM is a rare occurrence, but breast cancer is a much more frequent cause than prostate cancer and we reviewed 50 cases. Only 15 of cases of TMM from prostate cancer have been described.
Discussion And Conclusion: TMM is a rare phenomenon, but it is important to be aware of this as more and more patients live with cancer and meningiomas have a high prevalence, The possibility of TMM may impact not only both the surgical and oncological treatment but also surveillance of incidental meningiomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295949 | PMC |
http://dx.doi.org/10.1016/j.bas.2024.102862 | DOI Listing |
Breast Cancer Res
January 2025
Department of Breast Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Jiefang Road, Hangzhou, Zhejiang, China.
Background: Neoadjuvant chemotherapy (NACT) is the standard-of-care treatment for patients with locally advanced breast cancer (LABC), providing crucial benefits in tumor downstaging. Clinical parameters, such as molecular subtypes, influence the therapeutic impact of NACT. Moreover, severe adverse events delay the treatment process and reduce the effectiveness of therapy.
View Article and Find Full Text PDFBMC Cancer
January 2025
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, 37 Andre Cavalcanti Street, 5th floor, Annex Building, 20231050, Rio de Janeiro, Brazil.
Background: Breast cancer (BC) has exhibited varied epidemiological trends based on distinct age categories. This research aimed to explore the incidence and mortality rates of BC within pre-defined age groups in the Brazilian population.
Methods: BC incidence trends were assessed from 2010 to 2015 using Brazilian Population-Based Cancer Registries, employing age-standardized ratios and annual average percentage change (AAPC).
BMC Med Imaging
January 2025
Electronics and Communications, Arab Academy for Science, Heliopolis, Cairo, 2033, Egypt.
Invasive breast cancer diagnosis and treatment planning require an accurate assessment of human epidermal growth factor receptor 2 (HER2) expression levels. While immunohistochemical techniques (IHC) are the gold standard for HER2 evaluation, their implementation can be resource-intensive and costly. To reduce these obstacles and expedite the procedure, we present an efficient deep-learning model that generates high-quality IHC-stained images directly from Hematoxylin and Eosin (H&E) stained images.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
University of Pittsburgh School of Medicine (Center for Clinical Genetics and Genomics), Pittsburgh, PA, USA.
Breast Cancer Res Treat
January 2025
Department of Public Health Sciences, University of Virginia, 560 Ray C Hunt Dr., Room 2107, Charlottesville, VA, USA.
Purpose: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This study investigates these disparities in MBC treatment initiation, aiming to identify key factors crucial for improving timely access to care.
Method: Nationwide Flatiron Health electronic health records-derived deidentified database, including females aged 18+ diagnosed with either De novo or relapsed MBC in the U.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!